Overview
Professor Needham has been at Duke since 1987 and over the years has developed many collaborative and scholarly relationships across the campus and Medical School. He holds Faculty and membership appointments as: Associate Professor of Biomedical Engineering; Center for Bioinspired Materials and Material Systems; Center for Biomolecular and Tissue Engineering; Duke Comprehensive Cancer Center; and the Duke Cancer Institute. Internationally, he holds a joint appointment as Professor of Translational Therapeutics in the School of Pharmacy, at the University of Nottingham, UK. He also collaborates with preclinical researchers at the Erasmus University Medical Center, in Rotterdam, NL.
For the past 35 years Needham's Lab has developed and used a platform technology of micropipette manipulation to manipulate single and pairs of micro bubbles, droplets and particles in order to assess their behavior in well-defined fluids and solution conditions. Recently his research and development has focused on nucleation, growth and stability of nanoparticles. Applications of these fundamental particle and interfacial studies have primarily focused on advanced drug delivery treatments for cancer and now COVID19 with a nasal and throat spray prophylactic and early treatment regimen.
Current Appointments & Affiliations
Recent Publications
Niclosamide: A career builder.
Journal Article Journal of controlled release : official journal of the Controlled Release Society · May 2024 My contribution to honoring Professor Kinam Park celebrates and resonates with his scholarly career in drug delivery, his commitment to encouraging the next generation(s), and his efforts to keep us focused on clinically effective formulations. To do this ... Full text CiteLPS-aggregating proteins GBP1 and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro.
Journal Article Proc Natl Acad Sci U S A · April 11, 2023 The gamma-interferon (IFNγ)-inducible guanylate-binding proteins (GBPs) promote host defense against gram-negative cytosolic bacteria in part through the induction of an inflammatory cell death pathway called pyroptosis. To activate pyroptosis, GBPs facili ... Full text Link to item CiteSupplementary Data from Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma
Other · April 3, 2023 <p>Supplementary Materials including Text and Data</p> ... Full text CiteRecent Grants
Niclosamide spray as a prophylactic and early treatment for SARS-CoV-2
ResearchCo Investigator · Awarded by American Lung Association · 2021 - 2023TRP and AQP Channels: Modulation of Function, Raft Location by Membrane Lipids
ResearchConsultant · Awarded by National Institutes of Health · 1980 - 2015PLGA Protein Microspheres: Single Particle Engineering
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2011View All Grants